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Abstract
Background: Prevalence estimates from population-based surveys do not suffer from the same 
biases as case-report and clinic positivity data and may be better to monitor sexually transmitted 
disease morbidity over time.
Methods: We estimated the prevalence of Neisseria gonorrhoeae in a nationally representative 
sample of persons aged 14 to 39 years participating in the National Health and Nutrition 
Examination Survey.
Results: From 1999 to 2008, the overall prevalence of gonorrhea was 0.27% (95% confidence 
interval, 0.13%–0.47%). In the 2005 to 2006 and 2007 to 2008 cycles, prevalence approached 0% 
and was based on too few positive sample persons to obtain reliable estimates. In 2004, most 
infections were found in 1 survey location.
Discussion: Given the low prevalence and geographic clustering of disease, gonorrhea estimates 
from national probability surveys are often imprecise and unstable. In 2008, gonorrhea testing in 
National Health and Nutrition Examination Survey was discontinued. Continued surveillance of 
gonorrhea should include case reporting and prevalence estimates from local surveys and sentinel 
surveillance systems.
Infection with Neisseria gonorrhoeae can cause adverse reproductive health outcomes 
including infertility1 and can facilitate HIV transmission.2 Although gonorrhea burden has 
decreased significantly since the 1970s, it is still the second most common nationally 
notifiable disease in the United States, with 309,341 infections reported in 2010.3 Gonorrhea 
has pronounced racial disparities, with the reported case rate in blacks in 2010 more than 18 
times the case rate among whites.3 However, using case-report data to monitor trends in 
morbidity has challenges. Gonorrhea may be asymptomatic, particularly in females.1 
Increasing use of dual-diagnostic tests for chlamydia and gonorrhea combined with 
expanded chlamydia screening programs has likely increased the number gonococcal 
infections identified and reported independent of changes in prevalence. Conversely, 
increased prevention and control strategies, such as expedited partner therapy where sexual 
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partners of patients diagnosed as having gonorrhea are treated presumptively without clinical 
evaluation, may have led to a decrease in the number of infections identified and reported. 
Although poorly documented, rates of reporting detected infections likely vary by source of 
care and associated demographic factors, which change over time. Consequently, trends in 
case-report data are difficult to interpret.
To supplement national gonorrhea case-report data, trends in positivity data from patients 
tested for gonorrhea in sentinel sites including family planning, sexually transmitted disease 
(STD) and prenatal clinics are monitored.3–6 Although clinic positivity may be a reasonable 
approximation of clinic prevalence,7 it is likely an overestimate of prevalence in the general 
population because patients may be motivated to seek care because of symptoms or 
increased risk for gonorrhea (e.g., they have a partner with gonorrhea). In addition, trends in 
clinic positivity are influenced by changes in screening criteria, as well as changes in the 
population seeking care.8 Prevalence estimates from special populations such as entrants to 
the National Job Training Program (NJTP) are also used to monitor morbidity,3,9 but these 
estimates may not be representative of the general population. Thus, data from nationally 
representative surveys may be useful to better characterize the prevalence of gonorrhea in 
the US general population and to monitor trends in morbidity over time.
To provide nationally representative prevalence estimates, the National Health and Nutrition 
Examination Survey (NHANES) began testing participants for N. gonorrhoeae in 1999. An 
earlier report provided prevalence estimates from data collected from 1999 to 2002.10 Here 
we report estimates of gonorrhea from 5 cycles of NHANES (1999–2008), examining 
temporal trends and reporting estimated prevalence by age, sex, and race/ethnicity.
METHODS
The NHANES is a series of cross-sectional, household surveys collected in 2-year cycles 
using a complex, multistage, probability sampling design to select participants representative 
of the US civilian, noninstitutionalized population. National Health and Nutrition 
Examination Survey samples from 12 to 15 geographic locations per year; locations may 
vary from cycle to cycle. Low-income persons, Mexican Americans, non-Hispanic blacks, 
and adolescents (oversampled from 1999 to 2006 only) were sampled at higher frequencies 
to improve stability of estimates for these subpopulations. Participants 18 years or older 
provided written informed consent. For participants younger than 18 years, parents provided 
written consent along with minor’s assent. Data from participants collected during five 2-
year cycles (1999–2008) were analyzed. The study protocol was reviewed and approved by 
an institutional review board at the Centers for Disease Control and Prevention.
Participants were interviewed and examined. Urine from participants aged 14 to 39 years 
was tested for N. gonorrhoeae by nucleic acid amplification tests.11 From 1999 to 2002, 
Abbott Laboratories’ (Abbott Park, IL) LCx assay and, thereafter, the Becton Dickinson’s 
(Franklin Lakes, NJ) BDProbeTec assay were used according to the manufacturers’ 
instructions. Protocols for specimen testing and test result notifications have been described 
in a previous report.10
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We report the estimated prevalence of gonorrhea by age, race/ethnicity, and sex with 
corresponding 95% confidence intervals (CIs). Estimates were weighted to be nationally 
representative and to account for oversampling and nonresponse. Prevalence estimates with 
relative standard errors (RSEs) of more than 30%12 or based on less than 10 positives 
persons are noted and are considered unstable and should be interpreted with caution. We 
anticipated low estimated prevalence and small sample sizes based on findings from an 
earlier report.10 Given that we would likely be underpowered to detect statistical differences 
in subpopulations and in trends over time, we did not conduct statistical tests. Instead we 
provide 95% CIs as measures of precision of estimates.13 SAS-callable SUDAAN v10.0 
(RTI International, Research Triangle Park, NC) was used to account for the complex survey 
design when calculating standard errors.
RESULTS
Among the 20,836 participants aged 14 to 39 years selected to participate in NHANES from 
1999 to 2008, 17,190 (83%) were interviewed and 15,885 (92% of those interviewed) were 
examined and tested for gonorrhea for an overall response rate of 76%.14 In the 1999 to 
2000 cycle, 21 infections were identified among the 3145 participants sampled, a weighted 
prevalence of 0.25% (95% CI, 0.10%–0.49%; RSE, 31%). Prevalence was similar in 2001 to 
2002, with 15 infections found among 3487 participants (weighted prevalence, 0.20%; 95% 
CI, 0.08%–0.42%; RSE, 31%). Prevalence was highest in the 2003 to 2004 cycle (0.74%; 
95% CI, 0.18%–1.99%; RSE, 49%) based on 27 infections among 3211 participants; 
however, 9 of the 13 infections detected in 2004 were found in 1 survey location, which 
resulted in an increased variance as indicated by the large 95% CI. In the 2005 to 2006 and 
2007 to 2008 cycles, prevalence approached 0% and was based on too few positive sample 
persons (n = 7 and n = 2, respectively) to obtain reliable estimates. Although prevalence 
seemed to decrease over time, it was not possible to reliably estimate a percent decrease, 
given the instability of the estimates in the last 2 survey cycles.
Over the 10-year period, the overall weighted prevalence of gonorrhea among males and 
females aged 14 to 39 years was 0.27% (95% CI, 0.13%–0.47%; Fig. 1). Prevalence among 
females was 0.34% (95% CI, 0.16%–0.57%). Among persons aged 14 to 25 year, prevalence 
was 0.40% (95% CI, 0.20%–0.72%). Prevalence among non-Hispanic black males and 
females was 0.83% (95% CI, 0.56%%–01.20%) and was 0.18% (95% CI, 0.05%–0.44%; 
RSE, 44%) among males and females of other races/ethnicities. Among 14 to 25 year olds, 
prevalence was 1.82% (95% CI, 1.07%–2.89%) among non-Hispanic black females and was 
0.31% (95% CI, 0.11%–0.70%; RSE, 42%) among females of other races/ethnicities.
DISCUSSION
Currently, NHANES is the only nationally representative data source for gonorrhea 
prevalence in adults and adolescents. Findings from the 1999 to 2008 surveys document low 
overall national prevalence of infection (<0.5%) and significant racial disparities. The racial 
disparity was especially pronounced among young females. These data supplement national 
case-report data, as well as positivity and prevalence estimates from screened populations.
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Not surprisingly, the estimated national prevalence among females was lower than positivity 
found in STD clinics (state-specific median of 7% in 2000)4 and in family planning clinics 
(state-specific median of 1.3% in 2005–2007).5 The estimated prevalence in NHANES 
among 14- to 25-old-year males and females (0.40%; 95% CI, 0.20%–0.72%) is similar to 
the estimated 0.43% (95% CI, 0.29%–0.63%) prevalence among 18 to 26 year olds in the 
National Longitudinal Study of Adolescent Health in 2001 to 2002, a population-based 
survey of young adults.15 Prevalence of gonorrhea among entrants to the NJTP, a vocational 
program for socioeconomically disadvantaged youth aged 16 to 24 years, is generally higher 
than estimates from population-based surveys. In 2004, the prevalence among male NJTP 
entrants was 1.3% and was 2.6% among female entrants.9 However, the suggested decrease 
in prevalence over time in NHANES is similar to trends in prevalence among NJTP entrants. 
From 2004 to 2009, the odds of testing positive for gonorrhea decreased by 50% among 
female NJTP entrants and by 40% among male NJTP entrants.9
Using population data from the midpoint in the NHANES study period (2003/2004),13 an 
overall prevalence of 0.27% (95% CI, 0.13%–0.47%) translates to approximately 275,000 
prevalent infections (range, 135,000–489,000) among persons aged 14 to 39 years. Although 
symptom presence is not captured in NHANES, it is likely that most infections identified in 
NHANES were asymptomatic. From 1999 to 2008, there was an average of 314,000 cases of 
gonorrhea reported annually to Centers for Disease Control and Prevention among persons 
aged 15 to 39 years (range, 294,000–326,000).3 However, estimated prevalence and reported 
case counts are not directly comparable because case reports include both incident and 
prevalent infections. As such, reported case counts are expected to be higher than estimated 
prevalence in population surveys.
The diagnostic tests used to test for N. gonorrhoeae in NHANES are not 100% sensitive or 
specific, which may result in biased prevalence estimates. In particular, a low positive 
predictive value could result in overestimation of prevalence. There was a change in assay 
used (LCx was used from 1999 to 2002 and ProbeTec from 2003 to 2008). Both assays were 
cleared by the Food and Drug Administration for identification of gonococcal infection and, 
as such, have some degree of equivalence. No published studies directly compare the test 
performance characteristics of these assays; however, one study compared each with a third 
standard.16 In this study, ProbeTec had similar sensitivity and specificity to LCx. Although 
less pronounced than in case-report data, significant racial disparities exist with gonorrhea 
prevalence in non-Hispanic blacks higher than in other race/ethnic groups. Similar 
disparities have been noted in both the NJTP and clinic positivity data.5,9 Continued, 
targeted prevention and control efforts including screening and partner services to ensure 
partners are appropriately treated are needed to reach those most at risk. Because NHANES 
data are not available at the local level, targeting may need to be based on local case-based 
surveillance.
Prevalence estimates in NHANES do not suffer from the same biases as case-report data, 
such as differential case ascertainment based on differences in health care–seeking behavior, 
screening, and reporting practices, and as such may be better to monitor disease burden over 
time.8 However, we document that estimates from national probability surveys can be 
imprecise and may not reliably estimate low-prevalence diseases. In the last 2 survey cycles 
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of NHANES, very few infections were identified, and we were not able to reliably calculate 
prevalence estimates for those years. Consequently, we could not statistically examine 
temporal trends over the 5 cycles or quantify a change in prevalence. Although the low 
prevalence in the last 2 survey cycles suggests that prevalence may be declining, we are 
limited in our inference given the limits of the data. To provide age, sex, and race/ethnicity 
specific estimates, we assumed homogeneity across cycles and combined data from 10 
years. Still, many estimates had wide CIs.
The NHANES data are not available by region or state. Because gonorrhea is a 
geographically clustered disease,3 national estimates may fail to uncover important 
differences by region. In addition, clustering of disease can affect national prevalence 
estimates. The NHANES samples participants from different geographic locations each year 
independent of disease burden. Inadvertently sampling locations with high gonorrhea 
prevalence or finding a cluster can inflate national point estimates. Conversely, if only low-
prevalence areas are sampled, national estimates may look misleadingly low.
The NHANES is nationally representative, but the sample size is not sufficient to adequately 
assess important differences among subpopulations. Given the continued emergence of 
antibiotic-resistance gonorrhea,17 particularly among men who have sex with men (MSM), it 
is important to monitor trends in gonorrhea morbidity in MSM. Although sexual behavior 
and sexual identity data are captured in NHANES, we were not able to estimate prevalence 
among MSM, given the small sample size and low prevalence. Sentinel surveillance could 
be useful to provide this information. For example, the STD Surveillance Network (SSuN) 
provides enhanced data on gonorrhea positivity among MSM screened in selected STD 
clinics, as well as from enhanced data from a representative sample of reported cases.3,6,18
Although population prevalence estimates are valuable for monitoring gonorrhea, given the 
limitations of NHANES for monitoring low-prevalence diseases, testing for N. gonorrhoeae 
was halted at the end of 2008. Caution is needed when interpreting estimates based on 
existing data. National Health and Nutrition Examination Survey contains extensive data on 
the social and demographic characteristics of participants (e.g., health insurance status) and 
measures of self-reported sexual behaviors (e.g., number of sexual partners); however, given 
the small sample size and low prevalence of gonorrhea, subpopulation estimates would be 
unreliable and possibly misleading. Careful consideration must be given to the stability of 
the estimates when reporting prevalence estimates. Although NHANES is no longer used to 
monitor gonorrhea burden, it continues to be useful to population-based surveillance of other 
STDs such as Chlamydia trachomatis, human papillomavirus, and herpes simplex virus.19–21
Despite the limitations of the data, gonorrhea testing in NHANES from 1999 to 2008 
document low estimated population prevalence and significant racial disparities. Currently, 
no other nationally representative survey contains testing for N. gonorrhoeae. Continued 
surveillance of gonorrhea morbidity is needed and should include case reporting, as well as 
prevalence estimates from local surveys and sentinel surveillance systems.
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Prevalence of N. gonorrhoeae among 14 to 39 year olds by age, sex, and race/ethnicity, 
NHANES, United States, 1999 to 2008. Estimates with RSEs more than 30% or based on 
less than 10 positive sampled persons are considered unstable and should be interpreted with 
caution. Bars are 95% CIs. A, RSE more than 30% but less than 40%. B, RSE of 40% or 
more but less than 50%. C, Numerator less than 10 positive sample persons.
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